Coronavirus disease 2019 (COVID-19) is a pandemic that has influenced the whole world. It has spread rapidly since the first time it appeared in 2019 until today, creating a serious burden on the health systems in the countries. On the other hand, it has caused pneumonia in about 15% of the patients it infected with an approximate mortality rate of 5%. The main transmission route of the virus is the contact of infected respiratory droplets with the mucous membranes in the eyes, nose and mouth. Although it shows poor prognosis in older patients with more comorbid diseases, it can lead to severe clinical pictures in young patients and, more importantly, it can cause a serious public health problem by infecting individuals at risk through these patients. There is currently no effective treatment and vaccine for the disease. The most important step in the fight against infection seems to prevent transmission. There are studies in the literature reporting favorable outcomes with drugs like hydroxychloroquine, azithromycin, oseltamivir, favipravir and lopinavir / ritonavir. Pregnancy goes together with many immunological adaptive changes and pregnant population is more susceptible to infectious diseases. Therefore, discussions continue on issues such as the course of the disease in pregnant patients, its relation with obstetric complications, safe treatment approaches, prenatal follow-up and intrapartum management. The virus is thought to cause symptoms similar to the general population in pregnant women. Generally, flu-like clinical symptoms are observed. However, some studies have indicated increased risk for fetal distress and preterm labor in pregnancies complicated by COVID-19. Increased cesarean rates are also remarkable. Although there is no clear information about vertical transition, there are suspicious cases in the literature. Maternal death has been reported in only one case with a 30-week and 3-day pregnancy. Hydroxychloroquine and lopinavir / ritonavir combination is preferred in the treatment of pregnant patients. In order to protect the pregnant population, it is recommended to reduce the number of prenatal follow-up and the duration of the examination. In addition, both healthcare professionals and pregnant women who are examined should take the necessary personal precautions to reduce the risk of transmission. Again, health institutions should establish an appropriate management scheme to protect their staff and other patient populations. Management of suspicious cases should be ensured by a multidisciplinary team. In addition to maternal health, the protection of health personnel should be targeted in hospitals, and hospitals should designate isolated areas with negative pressure for the birth of these patients. Necessary information should be provided about the use of personal protective equipment, and the rules determined in the management of these patients should be followed carefully. In the postpartum period, the importance of breastfeeding should be taken into consideration along with the risk of neonatal transmission, and mother-baby attachment should be ensured by taking the necessary precautions. The purpose of this review is to review the results of pregnant women with COVID-19 infection on the basis of international literature and contribute to clinicians in the obstetric management of these pregnant women.